Shorter survival time seen in young prostate cancer patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 9
Volume 18
Issue 9

Young men with advanced forms of prostate cancer do not live as long as older men with similar forms of the disease, according to research conducted at the University of Washington in Seattle.

Young men with advanced forms of prostate cancer do not live as long as older men with similar forms of the disease, according to research conducted at the University of Washington in Seattle.

Daniel Lin, MD, and colleagues, mined the SEER database to identify 318,774 men diagnosed with prostate cancer between 1988 and 2003. Among men with advanced prostate cancers, the youngest men (ages 35 to 44) had a particularly poor prognosis, compared with older men. The younger men were more likely to die from cancer, or another cause, sooner than older men with similar forms of cancer (Cancer online, May 22, 2009).

The researchers suspect young men with advanced prostate cancer may have biologically more aggressive forms of the disease.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.